Resources from the same session
244MO - A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (“CLEVER”)
Presenter: Angela DeMichele
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Invited Discussant 243MO and 244MO
Presenter: Ava Kwong
Session: Mini oral session - Breast cancer, early stage
Resources:
Slides
Webcast